Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$8.43 USD
-0.56 (-6.18%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $8.42 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Cogent Biosciences, Inc. [COGT]
Reports for Purchase
Showing records 1 - 20 ( 126 total )
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -ASCO 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Bezu Playing Catch Up; Another Peek at the PEAK at ASCO
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
After a Disappointing Showing at ASH, Bezuclastinib Shows Signs of Promise Again; 2023 Financials; Raising PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Bezuclastinib Currently in "Show Me" Position; Lowering PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Bezu Falls from the SUMMIT; Downgrade to Neutral
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Workout at SABCS; Main Event at ASH
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for COGT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
APEX and SUMMIT Data Presentations at ASH; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R